References
- Magnuson TM, Roccaforte WH, Wengel SP, Burke WJ. Medication-induced dystonias in nine patients with dementia. J Neuropsychiatry Clin Neurosci. 2000; 12:219–25.
- Ozen S, Ariciogulları Z. Neuroleptic induced pharyngeal dystonia occuring at a conversion disorder backround: A case report. Psychopharmacol Bull. 2000; 10:28–32.
- Baldessarini RJ, Tarazi FI. Pharmacotherapy Of Psychosis And Mania. In Goodman & Gilman's The Pharmacological Basis of Therapeutics - 11th ed. USA: McGraw-Hill Companies, 2006:485–521.
- Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neuro. 2005; 252:1299–1306.
- Yis U, Ozdemir D, Duman M, Unal N. Metoclopramide induced dystoni in children: two case reports. Eur J Emerg Med 2005; 12:117–19
- Ozturk O, Kurt E, Oral T. Delayed-onset drug-induced movement disorders. Klinik Psikofarmakoloji Bülteni- Bulletin of Clinical Psychopharmacology 2006;16:266–73 (in Turkish).
- Pavlis CJ, Kutscher EC, Carnahan RM, Kennedy WK, Van Gerpen S, Schlenker E. Rivastigmin induced dystonia. Am J Health Syst Pharm. 2007; 1;64:2468–7.
- Dubow JS, Panush SR, Rezak M, Leikin J. Acute dystonic reaction associated with foscarnet administration. Am J Ther. 2008; 15 1846.
- Schneider SA, Udani V, Sankhla CS, Bhatia KP. Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs. Mov Disord. 2009; 15;24:1226–9.
- Liebelt EL, Francis PD. Dystoni. In: Goldfrank LR, Flomenbaum NM, Lewin NA, Howland MA, Hoffman RS, Nelson LS, eds. Goldfrank's Toxicology Emergencies. 7th ed. USA: McGraw-Hill Companies, 2002:847–864.
- Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry. 1988;145 869–71.
- Esen I, Demirpence S, Yis U, Kurul S. Cetirizine-induced acute dystonic reaction in a 6 year old boy. Pediatr Emerg Care. 2008; 24:627–8.
- Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol. 1989; 9:307–8.
- Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J. 1985 5;291(6500):930–2.
- Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008; 23, 1:15–26.
- Dilsaver SC. Antipsychotic agents: a review. Am Fam Physician. 1993; 47:199–204.
- Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005; 252:1299–306.
- Deshmukh P, Kulkarni G, Barzman D. Recommendations for pharmacological management of inpatient aggression in children and adolescents. Psychiatry (Edgmont). 2010; 7:32–40.
- Editorial Staff: Metoclopramid, (Management/Treatment Protocol). In: Klasco RK (Ed): POISINDEX® System. Thomson Micromedex, Greenwood Village, Colorado (Vol 142, expires 12/2009).
- Tighe MP, Afzal NA, Bevan A, Beattie RM. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs. 2009; 11:185–202.
- Kwon KT, Rudkin SE, Langdorf MI. Antiemetic use in pediatric gastroenteritis: A national survey of emergency physicians, pediatricians, and pediatric emergency physicians. Clin Pediatr (Phila) 2002; 41:641–52.
- Barach E, Dubin LM, Tomlanovich MC, Kottamasu S. Dystonia presenting as upper airway obstruction. J Emerg Med. 1989; 7:237–40.
- Kisa C, Aydemir C, Goka E. Temporamandibular joint dislocation due to orofacial distonia during antipysicotic use: A case report. Klinik Psikiyatri, 2007; 10:102–105 (in Turkish).